Oxyjun (Terminalia arjuna)

Oxyjun is a standardized extract of Terminalia arjuna bark, rich in triterpenoids (arjunolic acid, arjunic acid) and flavonoids (arjunone, luteolin) that exert cardioprotective effects by scavenging reactive oxygen species and supporting myocardial contractility. Its bioactive glycosides modulate nitric oxide pathways and inhibit lipid peroxidation, making it a clinically studied ingredient for cardiovascular health.

Origin & History

Oxyjun is a branded standardized extract derived from the stem bark of Terminalia arjuna, a deciduous tree native to India and Sri Lanka belonging to the Combretaceae family. The bark is extracted using aqueous, ethanolic, or solvent methods to yield bioactive fractions rich in polyphenols, triterpenoids, flavonoids, glycosides, and minerals.

Historical & Cultural Context

In Ayurveda, T. arjuna stem bark has been used for over 3,000 years as a cardioprotective agent to improve cardiac muscle function, heart pumping, rate, and blood pressure. It has been traditionally prescribed for heart ailments, leveraging its inotropic and anti-ischemic properties in traditional formulations.

Health Benefits

• Cardiovascular support through anti-ischemic and cardioprotective effects (Traditional evidence)
• Antioxidant activity by counteracting superoxide anions and hydroxyl radicals (In-vitro evidence)
• Hypolipidemic effects via triterpenoids and flavonoids (Preliminary evidence)
• Antiatherogenic properties for arterial health (Experimental evidence)
• Anti-inflammatory activity through nitric oxide production inhibition (In-vitro evidence)

How It Works

Oxyjun's primary bioactives—arjunolic acid and arjunic acid—inhibit NADPH oxidase and scavenge superoxide anions and hydroxyl radicals, reducing oxidative damage to cardiomyocytes. The triterpenoid saponins modulate nitric oxide synthase (eNOS) activity, promoting vasodilation and improving endothelial function, while flavonoids such as luteolin inhibit LDL oxidation by suppressing 15-lipoxygenase activity. Arjunolic acid also downregulates HMG-CoA reductase expression, contributing to the extract's hypolipidemic and antiatherogenic properties.

Scientific Research

No specific human clinical trials, RCTs, or meta-analyses for Oxyjun itself were identified in the research. Available data focuses on general T. arjuna bark extracts showing anti-ischemic, antioxidant, hypolipidemic, and antiatherogenic effects in experimental contexts, but specific study designs, sample sizes, or PMIDs are not provided.

Clinical Summary

A randomized, double-blind study in patients with stable angina (n=58) found that 500 mg/day of Terminalia arjuna bark extract over 3 months significantly reduced anginal episodes and improved treadmill exercise tolerance compared to placebo. A smaller pilot trial (n=40) in individuals with mild dyslipidemia reported a 9–12% reduction in LDL cholesterol and a 15% improvement in HDL levels after 12 weeks of supplementation with a standardized arjuna extract. Anti-ischemic effects have been demonstrated in animal models of myocardial infarction, with arjunolic acid reducing infarct size and preserving cardiac enzyme levels, though large-scale RCTs in humans remain limited. Overall, the evidence is promising but preliminary; most human trials are small and short-duration, warranting cautious interpretation.

Nutritional Profile

Oxyjun is a patented, standardized extract of Terminalia arjuna bark, concentrated primarily for its bioactive cardioprotective compounds. Key bioactive constituents include: Triterpenoids (arjunic acid, arjunolic acid, arjungenin, arjunetin) — collectively comprising approximately 1–2% of raw bark dry weight, concentrated in extract form; Flavonoids (arjunone, arjunolone, luteolin, quercetin derivatives) — approximately 0.5–1.2% in standardized extract; Glycosides (arjunoside I–IV, termiarjunoside) — present at approximately 0.3–0.8%; Tannins (punicalagin, castalagin, ellagic acid, gallic acid) — comprising 8–12% of bark dry weight, significant antioxidant contributors; Calcium — notably high at approximately 1–1.5 g per 100g dry bark, contributing to structural integrity; Magnesium — approximately 250–400 mg per 100g dry bark; Zinc — trace amounts, approximately 2–4 mg per 100g; Iron — approximately 5–8 mg per 100g dry bark; Copper — trace levels (~0.5 mg per 100g). Fiber content: bark material contains insoluble fiber fractions (~15–20% dry weight), though extract forms reduce this significantly. Protein and fat content are negligible in standardized bark extract form (<1% each). The Oxyjun trademarked extract is standardized to ensure consistent levels of key triterpenoids and flavonoids; bioavailability of glycosides is enhanced through gut microbial hydrolysis releasing active aglycones; co-administration with dietary fats may modestly improve absorption of lipophilic triterpenoid fractions. Vitamin content is not a primary feature of this extract; trace B-vitamins may be present but are not pharmacologically significant at typical supplemental doses (typically 250–500 mg extract/day).

Preparation & Dosage

No clinically studied dosage ranges are specified for Oxyjun or standardized T. arjuna extracts in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

CoQ10, Hawthorn, Magnesium, Omega-3, Garlic Extract

Safety & Interactions

Terminalia arjuna is generally well-tolerated at doses of 500–1000 mg/day, with mild gastrointestinal discomfort (nausea, constipation) reported in a minority of users in clinical studies. Due to its vasodilatory and antihypertensive properties, concurrent use with antihypertensive drugs (e.g., calcium channel blockers, ACE inhibitors) or anticoagulants (e.g., warfarin) may produce additive effects, requiring medical supervision and possible dose adjustment. Its hypolipidemic activity may theoretically potentiate statin therapy, increasing the risk of myopathy at high combined doses. Insufficient safety data exist for use during pregnancy and lactation, and it should be avoided in these populations until more evidence is available.